28/06/2016 02:02:43 1-888-992-3836 (toll free) Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

06/27/20166:59AMBWBristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food & Drug Administration fo...
This milestone marks the sixth Breakthrough Therapy Designation for Opdivo Bristol-Myers Squibb intends to file a marketing application with health authorities based on results from Phase 2 study CA209-275 and other supporting data Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration... More...>>
06/24/20164:10PMBWSickle Cell Partnership Creates Demonstration Project to Treat Children in Angola
The Angola Sickle Cell Initiative, a public-private partnership of the Angola Ministry of Health, the Baylor College of Medicine International Pediatric AIDS Initiative (BIPAI), Texas Children’s Hospital and Chevron, is teaming up with the global biopharmaceutical company Bristol-Myers Squibb to provide children with... More...>>
06/20/20164:15PMBWMurdo Gordon Appointed Executive Vice President and Chief Commercial Officer
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Murdo Gordon has been appointed executive vice president and chief commercial officer, a newly created position, effective June 21, 2016. Gordon will be responsible for leading the execution of commercial strategy across geographies. In this role, he will lead... More...>>
06/14/20167:40AMPRNUSTechnical Recap on Drug Manufacturers - Major Equities - Bristol-Myers Squibb, Eli Lilly, AstraZeneca, and GlaxoSmithKline
Technical Recap on Drug Manufacturers - Major Equities - Bristol-Myers Squibb, Eli Lilly, AstraZeneca, and GlaxoSmithKline PR Newswire NEW YORK, June 14, 2016 NEW YORK, June 14, 2016 /PRNewswire/ -- On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial... More...>>
06/10/20162:30AMBWNew Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Pa...
Opdivo demonstrated objective response rate of 66.3% in classical Hodgkin lymphoma patients who had relapsed or progressed after auto-HSCT and subsequent brentuximab vedotin, as assessed by an independent radiologic review committee Among patients who responded to Opdivo, estimated median duration of remission was 7.8... More...>>
06/09/201610:00AMBWBristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter of 2016 on Thursday, July 28, 2016. During a conference call at 10:30 a.m. EDT on July 28, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are... More...>>
06/09/20166:59AMBWBristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion & Immuno-Oncology Advancements Across Mul...
Presentation of Opdivo CheckMate -205 registrational trial reports on objective response rates and ongoing responses in patients with classical Hodgkin lymphoma who had relapsed or progressed after auto-HSCT and post-transplantation brentuximab vedotin New analysis evaluating impact of time from diagnosis and prior lines... More...>>
06/08/20167:48AMBWBristol-Myers Squibb Announces New Rheumatoid Arthritis Research & Real-World Data at the Annual European Congress of Rheumat...
Presentation of the first U.S. observational study exploring the impact of biomarkers on treatment response for Orencia and TNF-inhibitors in moderate to severe rheumatoid arthritis In this study, patients who tested positive via a common blood test for certain biomarkers of poor prognosis (anti-CCP or RF) were more likely... More...>>
06/07/20164:15PMBWBristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-eight cents ($0.38) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on August 1, 2016, to stockholders of record at the close of business on July 1... More...>>
06/07/20166:59AMBWBristol-Myers Squibb and MD Anderson Announce New Research Collaboration in Immuno-Oncology Focused on Lung Cancer
Bristol-Myers Squibb Company (NYSE:BMY) and The University of Texas MD Anderson Cancer Center today announced a new clinical research collaboration to evaluate innovative strategies for the potential use of Bristol-Myers Squibb’s immuno-oncology (I-O) agents Opdivo (nivolumab) and Yervoy (ipilimumab) to treat early... More...>>
06/06/20166:59AMBWLong-Term Data from Two Trials Evaluating the Opdivo® (nivolumab) & Yervoy® (ipilimumab) Regimen in Advanced Melanoma Conti...
Significantly longer progression-free survival and higher objective response rates with Opdivo and Yervoy combination and Opdivo monotherapy versus Yervoy alone, with a minimum of 18-month follow-up, from CheckMate -067 In CheckMate -067, median duration of response had not been reached with the combination regimen, and... More...>>
06/05/201611:24AMBWLong-Term Survival & Improvement in Quality of Life Observed with Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma Patie...
More than one-third (34%) of previously treated advanced renal cell carcinoma patients who received Opdivo were alive at five years, in the Phase 1 study, CA209-003 In the Phase 2 study, CA209-010, 29% of previously treated advanced renal cell carcinoma patients who received Opdivo were alive at four years Improved health-related... More...>>
06/05/20169:00AMBWFirst Presentation of Phase 2 CheckMate -142 Study Evaluating Opdivo® (nivolumab) Alone or in Combination with Yervoy® (ipi...
Investigator-assessed objective response rate for MSI-high metastatic colorectal cancer patients was 25.5% for Opdivo monotherapy and 33.3% for Opdivo in combination with Yervoy Six-month progression-free survival rates were 45.9% for Opdivo monotherapy and 66.6% for Opdivo in combination with Yervoy in patients with MSI-high... More...>>
06/05/20168:06AMBWPromising Response Rates with Opdivo® (nivolumab) Observed in Advanced Form of Bladder Cancer from Phase 1/2 Study CheckMate...
Confirmed objective response rate was 24.4% in these previously treated patients who received Opdivo Similar response rates were observed regardless of PD-L1 expression status; in patients with PD-L1 <1%, the objective response rate was 26.8%, and in patients with PD-L1 ≥1%, the objective response rate was 24% At... More...>>
06/04/20162:27PMBWOpdivo® (nivolumab) & Yervoy® (ipilimumab) Combination Regimen Shows Clinically Meaningful Responses in First-Line Advanced...
Confirmed objective response rate in patients with >1% PD-L1 expression for both Opdivo and Yervoy combination regimen cohorts was 57%, a doubling of response rate previously reported in Opdivo monotherapy arm Combination regimen cohorts showed enhanced efficacy with increasing PD-L1 expression, with up to a 92% response... More...>>
05/31/201610:30AMBWBristol-Myers Squibb to Take Part in Goldman Sachs 37th Annual Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in Goldman Sachs 37th Annual Global Health Care Conference on Tuesday, June 7, 2016, in Rancho Palos Verdes, CA. Michael Burgess, senior vice president, Exploratory Clinical and Translational Research, will answer questions about the company at 5 p.m. EDT (2 p.m. PDT... More...>>
05/23/20164:40PMDJNSamsung Targets U.S. Drug Market With Remicade Knockoff
SEOUL—Samsung Group said Tuesday its near-replica of Johnson & Johnson's blockbuster arthritis drug Remicade has been accepted for review by the U.S. Food and Drug Administration, marking the South Korean conglomerate's first attempt to sell drugs to Americans, alongside its popular smartphones and... More...>>
05/23/201611:15AMBWBristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
Bristol-Myers Squibb Company (NYSE: BMY) will host a teleconference on Saturday, June 4, 2016, at 7 p.m. EDT (6 p.m. CDT) to discuss company strategy and review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of company... More...>>
05/19/20167:55AMGLOBEInovalon Announces Agreement with Bristol-Myers Squibb to Focus on Real World Outcomes & Value-Based Contracting Initiatives
BOWIE, Md., May 19, 2016 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based analytics and data-driven intervention platforms to the healthcare industry, today announced that it has entered into an agreement with Bristol-Myers Squibb (NYSE:BMY), a global BioPharma company... More...>>
05/18/201610:27PMDJNNew Hope for Melanoma Patients -- Update
By Peter Loftus A new study reinforces the potential of a new class of expensive immune-boosting drugs to prolong the lives of people with a deadly form of skin cancer. An estimated 40% of 655 people who took Merck & Co.'s Keytruda in a clinical trial to treat advanced melanoma were still alive three years after... More...>>
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20160628 06:02:43